BRCA1 and endometrial cancer: In order to test the effect of WEE1 inhibition as a single intervention on gynecological cancer cells, the endometrial cancer cell lines, Hec50 and KLE, and the ovarian cancer cell line OVCAR3, which are wild-types for BRCA1/2, were treated for 72 h with different concentrations of the WEE1 inhibitor AZD1775.